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Dr. Martine J. Jager is Professor of Ophthalmology, especially Ocular 
Melanoma, at Leiden University, The Netherlands. She received her 
MD degree and PhD in Immunology from Leiden University, did her 
residency in Ophthalmology at the University of Amsterdam, and a 
research and clinical ocular surface fellowship at the Bascom Palmer 
Eye Institute in Miami. She is a frequent visitor at the Schepens Eye 
Research institute, Harvard Medical School, Boston, where she holds 
a position as adjunct scientist. Her research interests are immunology 
and development of uveal melanoma, and ocular surface diseases, on 
which subjects she has published over 200 peer-reviewed papers as 
well as three books and over 40 book chapters. She is International 
Advisor and Guest Professor at Peking University, Bejing, China.
She mentors medical students and PhD student in the Netherlands 
as well as abroad. She has lectured worldwide, and has been principal 
investigator on numerous grants dealing with the development and 
immunology of uveal melanoma. Many projects involve international 
collaborations.
Dr. Jager has served as President of the Association for Research in 
Vision and Ophthalmology (ARVO), is a member of the Advisory 
Board of the International Council of Ophthalmology, and of the 
Academia Ophthalmologica Internationalis. She was recently elected to 
become the President of the International Society of Ocular Oncology.
Ocular melanoma is a rare type of cancer, with a high chance of metastases. 
Metastases of conjunctival and uveal melanoma are often resistant to 
therapy, including to immunological treatments. For uvea melanoma, this 
may be due to the environment in which this tumor arises, which is inside 
the eye. The eye has many immunological peculiarities: it is a location 
with immune privilege, which means that immune responses are down 
regulated. This has the advantage that corneal transplants will be accepted 
in a non-inflamed recipient cornea and thus usually not rejected. On the 
other hand, this immune privilege allows viruses such as ebola to proliferate 
inside the eye. Similarly, in mouse experiments, tumor cells may not be 
rejected when placed inside the eye, while they would be rejected when 
injected in the skin. Professor Jager’s research is focused on obtaining a 
better understanding of the influence of this immune privilege on the 
behavior of human ocular tumors, and on the possibilities of still using the 
immune system to develop an effective therapy to treat metastases of ocular 
melanoma.
In order to develop good research, (inter)national collaborations are 
essential. Within the LUMC, the department of Ophthalmology collaborates 
with the laboratories of Clinical Oncology, Immunohematology and 
Blood Transfusion, Human Genetics and Dermatology, among others. 
Collaborations also exist with the department of Ophthalmology and 
Clinical Genetics of the Erasmus MC, Rotterdam. Internationally, the 
research group of Professor Jager participates in the European Ocular 
Oncology group (which has led to the Horizon2020 Cure UM collaborative 
group), the International Society of Ocular Oncology, the American Joint 
Committee on Cancer and The Cancer Genome Atlas Project.
As a cornea specialist, Professor Jager treats patients with severe corneal 
and ocular surface diseases, searching for better treatments. A second 
international consortium, Horizon Arrest Blindness group, focusses on 
the immunological aspects of the cornea and stem cells, with the goal of 
developing an artificial cornea. 
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Rector Magnificus, members of the Board of the Leiden University 
Medical Center, dear attendees,
Last year, you had the opportunity to participate in the 
National Science Agenda, which is going to be used for 
planning scientific research in the Netherlands: you could 
propose items for research. Many proposals were related to 
health: “How is knowledge about genetics going to help us 
understand the screening and treatment of (rare) diseases? 
How can we develop new drugs to help us stay healthy into old 
age?” And another one: “Every tumor is different: how can we 
get enough knowledge to treat each type of malignancy?”
A lot of research takes place in Academic centers, which 
responded quickly with a joint National Plan Academic Health. 
This plan proposes plans for prevention, early detection, 
individual care (known as personalized medicine) and costs. 
I quote: “Scientific collaboration and innovation are the key 
words to use the available resources as efficiently as possible. 
Only with such an approach will we be able to keep Europe 
above average in science and to excel in the international 
scientific league.” In size, The Netherlands is a small country, 
but especially our Academic centers such as the LUMC deliver 
an internationally high scientific output.
In the next 45 minutes, I will discuss some of the items 
mentioned in the National Science Agenda, as they are 
relevant for the eye and the subject of my professorship: 
the eye melanoma. The Dutch Federation of Universities 
has recognized the Department of Ophthalmology of the 
LUMC as the Center of Excellence for eye melanoma and 
excellent medical care needs to be combined with research. 
We ask ourselves: what are we doing right, what can we do 
better? I will first discuss the importance of education and 
of collaborations, including international ones. After this, I 
will discuss the peculiarities of the eye and the influence of 
the intraocular environment on intraocular tumors as well as 
systemic tumor growth. I hope that after my presentation, you 
will understand that the eye has unusual features with regard 
to the immune system, and that those are relevant to tumors, 
tissue transplants, and ocular infections. I hope to open your 
eyes to all of this.
The uveal melanoma
Eye melanoma are rare tumors, they can develop on the ocular 
surface, where they are known as conjunctival melanoma 
and inside the eye, which is the uvea melanoma. My story is 
about this latter tumor. It is called uvea melanoma, because it 
develops in the uvea (named after a grape). The uvea is made 
up of the iris, the ciliary body, which produces our ocular fluid 
and the choroid. These three locations contain melanocytes, 
just like the skin, which can develop into malignancies. 
People with a light skin and blue eyes do not only carry an 
increased risk to develop cutaneous melanoma, but also of 
uvea melanoma. In The Netherlands, we have about 200 new 
cases a year and people are usually between 50 and 70 years 
old. This malignancy may however also occur in younger 
people. I would like to introduce Mrs. A to you: when she 
was 39-years old, her vision decreased in one eye and she 
consulted an ophthalmologist. A uvea melanoma was found 
and she was directed to the LUMC. Our ophthalmologists and 
radiologists are very experienced in treating the intraocular 
tumor; this tumor was treated with a radio-active plaque. The 
tumor regressed and her vision returned to 90%. However, 
four years later, Mrs. A developed a single metastasis in the 
liver, found thanks to regular screening. This metastasis 
was treated with radiofrequency ablation. What can we do 
when she develops new metastases, elsewhere in the body? 
Regrettably, up to 50% of patients may develop metastases. 
Currently, no systemic treatments are available. In some cases, 
radiofrequency treatment, liver resection, or liver perfusion 
with chemotherapy are successful, but often, the metastases are 
not sensitive to any existing drugs. 
Furthermore, what is striking, is the young age of Mrs. A. In 
addition, her father developed cancer of the gut, her mother a 
cutaneous melanoma, and she has blue eyes and many nevi on 
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her back. Why did she develop an eye melanoma?
Please recall the questions of the National Science Agenda: 
“How is knowledge about genetics going to play a role in 
understanding cancer, and how can we understand cancer well 
enough to treat every type of malignancy?”
Travel in the world
This one patient indicates that we are able to do a lot, but 
we have to learn more about the genetics and the biological 
behavior of the tumor, in order to develop new treatments. We 
do not yet know the gene(s) that play(s) a role in this patient’s 
melanoma at this early age. Research is difficult when you work 
with small numbers, and only by collaborating with similarly-
interested researchers in many countries can one obtain enough 
knowledge. In The Netherlands, we collaborate with Rotterdam 
and internationally with many centers. Much of the research 
work in our department is performed by PhD students and 
medical and biomedical students. 
To learn about the newest developments, our students visit 
the yearly congress of the association of Research in Vision 
and Ophthalmology (ARVO), the largest congress in scientific 
ophthalmology. It is important for students to spend time 
abroad for research and their own education. I want to illustrate 
this with a story, from another time and in another place.
“The hero of my story is Tiuri. This Tiuri had performed 
all the necessities to become a knight, he would be knighted 
the next day. He spent the night prior to his great day in a 
chapel, amongst his peers, when he heard a voice, asking for 
help. Tiuri was the only one who heard the voice and decided 
to go outside and help. This subsequently led him on a long 
voyage, wherein he met many interesting people, made 
friends, and visited a strange country. Upon returning home 
from his travels, he saw his friends, who had been knighted, 
riding beautiful horses. He wondered: “I could have been one 
of them, if I had not listened to that voice” but he knew that 
he did not want things to be different, as he would not have 
missed his experiences.
For those who do not know my story: Tiuri is the hero of the 
book “The letter for the King” by Tonke Dragt. This book was 
chosen as the most important children’s book of the prior 
century. Tiuri describes an experience that is shared by many 
students that have worked abroad. Andrea, a Brazilian student 
who worked in our lab, wrote this, after she had returned to 
Brazil: “I got so lost: I changed so much, and nobody else did. 
Things are getting better now, but at the beginning it was really 
hard to get used again.”
A Dutch student, Anne, who did her rotation in 
Ophthalmology in Nepal, wrote: “My trip was crazy and life-
changing. Out of my comfort zone, which was an exceptional 
experience. Although I refer to my experience with Nepal 
in general, my stay at the Himalaya Eye Hospital certainly 
contributed to this.”
Many students that went abroad, left as children and came 
back as adults. The LUMC considers it important that its 
students spend some time abroad, as is currently the case in 
70% of students.
Since 1996, we have continuously had students at the Schepens 
Eye research Institute, Harvard Medical School, Boston. As 
a student, I first experienced lab work in Edinburgh, and 
subsequently worked as an ophthalmologist and researcher 
in Miami and Boston. As adjunct scientist at Harvard, and 
professor in Bejing, I had the pleasure to experience other 
cultures, and this experience has influenced much of my work.
Function of the eye
Prior to discussing my scientific research, I would like to share 
with you the functions of the eye. Let’s go back to Tiuri. After 
following the voice, he had to travel through a forest, where 
he saw movement: when he looked carefully, he saw figures in 
the distances and the glittering of weapons. He needed several 
important functions of the eye: seeing movement, color, 
visual acuity and depth. He saw the figures because of a well-
functioning peripheral vision and excellent contrast vision. 
This is only possible when all parts of the eye function well: 
signals have to travel from the front of the eye, through the 
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lens, to the retina in the back of the eye, and subsequently to 
the brain.
Many of us need a simple object to see well, either in the 
distances or nearby. Would those who use glasses or contact 
lenses please put up their hand?
The eye takes care of the first step of seeing, for which it is 
important to have clear media. The media are the tissues that 
we look through and the fluids of the eye. The most important 
causes of blindness in the world are clouding of the lens (nr 1) 
and diseases of the cornea (nr 2), the outer layer in the front of 
the eye. One can elegantly remove the lens (cataract surgery), 
and for instance the Lions Working Group for the Blind tries 
to help to reduce cataract blindness worldwide.
When the cornea is cloudy, it can be transplanted. According 
to old books, it cannot be rejected, but that is only the case 
when the cornea is not inflamed and has no blood vessels. 
The healthy cornea contains many molecules that can indeed 
inhibit immune responses. This phenomenon is known as 
immune privilege.
Ocular immune privilege
A foreign body is not easily recognized when it is placed inside 
the eye. I ran into a thesis from 1873: “About the consequences 
of placing living tissues and dead objects in the eye” by J.C. 
van Dooremaal, a pupil of Donders. Van Dooremaal looked 
at what happened when one introduces different materials 
such as cork, wood, or tissues into the anterior chamber of 
the eye. He placed a piece of skin from a new-born mouse 
in the eye of a large dog. The piece of skin was encapsulated, 
the media (cornea and lens) remained clear. When this tissue 
had been placed in the skin, this would have led to a severe 
inflammation.
That immune reactions are suppressed in the eye was 
demonstrated again in 1946 by Medawar, who named this 
immune privilege. It is also known as ACAID, anterior 
chamber associated immune deviation, and further 
investigated by my teacher in Miami and Boston, professor 
Wayne Streilein. The eye shares this active immune 
suppression with the brain, the testis and the uterus. The local 
immune tolerance allows the fetus to grow in its mother’s 
uterus, although half the tissue characteristics in the child 
come from the father. Recently, the immune privilege of 
the eye and the testis became world news. Men that have 
survived an ebola infection still had the virus in their semen 
months after the infection seemed to have disappeared. The 
eye reached the news as well: Dr Crozier described that he 
developed an inflamed eye three months after recovery from 
ebola. His inflamed eye was shown to harbor incredible 
amounts of virus, as the only known location in his body. 
The anterior part of the eye
The advantage of immune privilege is the easy acceptance of 
corneal transplants, as I already mentioned. The local immune 
privilege, however, makes the eye more sensitive to infections. 
We see this in the easy development of corneal bacterial ulcers 
in people wearing contact Lenses, and the development of 
infections after cataract surgery. The fluids and tissues in the 
eye actively suppress immune responses, up to a certain level. 
After that, the inflammation is no longer inhibited, and we will 
find inflammatory cells (lymphocytes and macrophages) in the 
cornea, as well as vessel ingrowth. At that stage, donor cornea 
can be rejected. When a donor cornea is placed on an inflamed 
recipient cornea, transplant rejection can occur. Such a 
response is directed against the proteins of the HLA system, the 
tissue histocompatibility antigens, in 1958 discovered here in 
Leiden by Van Rood. The chance of rejection can be decreased 
by matching donor and recipient for these HLA antigens, 
as has been demonstrated by the Leiden ophthalmologist 
professor Völker-Dieben. However, the chance of rejection 
may be such, that performing a transplant is not a good idea. 
By transplanting either only the front or the back of the 
cornea, Melles from Rotterdam has been able to reduce the 
chance of rejection already. This lamellar technique that he has 
developed is now being used worldwide.
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Where a clouded lens can be replaced by an artificial lens, we 
still rely on human material for replacing damaged corneas. 
There is a chronic shortage. Developing an artificial cornea 
made of a fish scale is one of our areas of interest, together 
with the Leiden company Aeon Astron and the members of the 
Horizon2020 group Arrest Blindness. 
Tumors in the back of the eye
I just discussed the ocular immune privilege, which allows 
the acceptance of a cornea transplant in a quiet eye. A 
disadvantage is that the eye is less resistant to infections. 
Another aspect is that, tumor cells that would be rejected 
elsewhere in the body, can grow inside the eye. Leiden has 
been the main eye cancer center since the 70ties, especially for 
eye melanoma. I already told you about Mrs. A. Her primary 
tumor can be treated properly with a radioactive plaque. In 
the near future, we may do this even more precisely with the 
new proton facility that is being built in Delft. However, our 
options for treatment of metastases are still limited.
MABJES
Are you ever home on time to watch “De wereld draait 
door”? On March 9, Haanen explained the data of a recent 
paper published in Science. New research suggested that we 
should be able to treat all types of cancer with immunological 
techniques. Let us hope so. One of the new approaches in 
personalized medicine is the use of monoclonal antibodies, 
with so-called Mabjes. These are being applied successfully 
in cutaneous melanoma and kidney cancer. The newspapers 
reported the discussion between minister Schippers and 
pharmaceutical companies. For one drug, Nivolumab, the cost 
was originally estimated at 134.000 € per survival year. What 
do these Mabjes do? A comparison: their activity is similar to 
placing little corks on the spines of a sea urchin: the enemy 
can now attack. It works the same with the attacking cell of 
the immune system, the lymphocyte can now attack the tumor 
cell: the Mabje has disabled the defense of the tumor cell.
The treatment is expensive, but works very effectively in some 
patients with cutaneous melanoma or lung cancer. We need the 
same for eye melanoma!
Immunology of eye melanoma
Why would a cornea doctor study eye melanoma? Expression 
of HLA antigens is considered important in immune attacks. 
I wanted to study that in cornea transplantations. Others were 
looking into the role of HLA antigens in cancer. Professor 
Ruiter in Leiden studied cutaneous melanoma, and suggested I 
would not only look at corneas but also at ocular malignancies, 
especially uvea melanoma. We observed that some uvea 
melanoma had a low and others a high HLA expression. 
Those with a high expression also had a lot of macrophages 
and lymphocytes. One would expect these tumors to be 
the ones that would get rejected, as was the case in cornea 
transplantations. And one would expect that inflamed tumors 
would not develop metastases. Surprisingly, it was the other 
way around. 
Maat and Bronkhorst studied which inflammatory cells 
occurred in uveal melanoma, and the cells were found to carry 
many immunosuppressive characteristics. Does the eye itself 
play a role, just as what happened when Dooremaal introduced 
mouse skin in the eye of a dog?
Together with Toes and Kast, Schurmans and Boonman, 
we set up the first mouse ocular tumor model in mice, and 
studied the effect of placing tumor cells in the eye. We noticed 
a striking phenomenon: after placing tumor cells in the eye, 
they were also no longer recognized when injected in the 
skin. Placing tumor cells inside the eye had inhibited the anti-
tumor immune response in the whole body. This is where the 
Mabjes should come in, to block the immunosuppressive effect 
of tumor cells. However, the first clinical results have been 
disappointing, and we intend to research this area extensively 
in the coming years. Why do the Mabjes often work well in 
treating metastases of cutaneous melanoma but not those of 
eye melanoma?
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Macrophages
Why do tumors with many macrophages more often give rise 
to metastases than tumors with a few macrophages? We already 
know a lot about the characteristics of uveal melanoma that 
will lead to metastases. One often sees loss of one chromosome 
3 and that has been identified as the most important 
prognostic factor. Maat and Bronkhorst reported that the 
inflammatory phenotype, that contains high numbers of T 
cells, macrophages and an increased HLA expression, occurs 
especially in tumors with loss of one chromosome 3. This has 
recently been acknowledged by The Cancer Genome Atlas, an 
international study on 80 cases of uvea melanoma.
Several different types of macrophages have been described: 
M1 macrophages, which can stimulate the immune system, 
for instance against infectious diseases and M2 macrophages, 
which may repair tissue damage and can help to build blood 
vessels. A tumor needs blood vessels to grow, and a uvea 
melanoma has many more vessels than a benign naevus. When 
we studied a series of uvea melanoma, we noticed that tumors 
with a lot of macrophages also had many blood vessels, as 
has previously been described by Kivelä. And as Bronkhorst 
showed here in Leiden, those macrophages belong mainly to 
the pro-angiogenic M2 type. The blood vessels form a highway 
for metastases to migrate to the liver. Just think of Mrs. A.
We had a nice hypothesis: if the tumor macrophages belong 
to the M2 type, which is pro-angiogenic, one has to deplete 
macrophages in order to stop tumors from growing. We 
tried this in a mouse model. To our surprise, it did not work 
in young mice. However, many eye diseases only develop in 
elderly patients and we already know from research on macular 
degeneration, that age plays a role in macrophage function. 
We did the same experiments in old mice: after macrophage 
depletion, hardly any tumor growth occurred! Our theory was 
right, macrophages play a role in intraocular tumor growth, 
but only in elderly mice.
Studies involving the eyes of normal old mice revealed that 
their eyes already contained many more macrophages than the 
eyes of young mice. This phenomenon has become known as 
age-related para-inflammation, and this is also seen in humans. 
Our PhD student Khanh Vu has shown in the laboratory of 
Professor Dong Feng Chen in Boston that macrophages are 
also important in glaucoma, another age-related disease.
Importance for patients
How does this help the patient? The LUMC is an important 
player in the field of T-cell mediated therapies in cancer, 
especially in cutaneous melanoma. Why do we then not treat 
metastases of uvea melanoma patients with T cells? This 
has been tried, but this was not a success. It seems that the 
immunosuppressive forces of the eye have been transferred 
to the tumor’s metastases. We are going to investigate how we 
can modify this immunosuppression and will study why it 
is so hard to kill the uvea melanoma cells. What makes them 
resistant? Can we find any drugs that can attack the tumor cells 
in culture or in a zebrafish or mouse model? And combine this 
with immunotherapy? Furthermore, we will study the early 
beginning of melanoma. How do macrophages stimulate the 
change from nevus to melanoma? What is the role of having a 
blue eye? 
Together with Van der Burg, Jochemsen, Van Hall, Snaar, and 
Van der Velden we will try to develop a new treatment.
We are very happy with the already started plans of the 
Board of the Leiden University Medical Center to bring the 
oncology researchers together, especially of the Departments 
of Ophthalmology, Oncology and Dermatology. We hope 
that the current collaboration will be further strengthened by 
the development of one oncology laboratory, so that we will 
not only work together in mind. As I already mentioned, we 
collaborate within the Medical Delta with Annelies de Klein 
and Rob Verdijk van Erasmus MC to understand more about 
the role of chromosome aberrations and the behavior of ocular 
tumors. Internationally, we collaborate in the Horizon2020 
CURE UM project with the universities of Liverpool, 
Birmingham, Krakow, Trento and with the Champalimaud 
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Institute in Portugal. By collaborating with professors Michelle 
Madigan in Sydney, Bruce Ksander and Dong Feng Chen in 
Boston, we learn more about the role of macrophages in ocular 
tumor development and aging.
Conclusion
I have discussed with you the special characteristics of the 
immune system of the eye and explained that all kind of 
immunological processes work different in the eye than 
elsewhere in the body. This immune tolerance may lead to the 
acceptance of tissue transplants, but on the other hand may 
allow viruses and tumor cells to proliferate. We want to try 
to modify the immune system in such a way, that the body 
may learn to attack tumor metastases so that eye melanoma 
patients will also benefit from the new developments that 
benefit so many other cancer patients.
Thanks to the support of the Royal Netherlands Academy of 
Arts and Sciences I had the chance to study in Miami, and 
thanks to the support of the Macropa Foundation and the 
Haags Oogheelkundig Fonds, I was able to set up a lab here in 
Leiden to study the immunology of corneal transplantation 
and eye melanoma. The meetings of the Department of 
Immunohematology, especially those held on the Eendracht 
and the Dageraad, opened my eyes for the international world 
of research and showed me the importance of international 
collaboration. With our participation in The Cancer Genome 
Atlas Project, the American Joint Committee on Cancer, 
already 18 PhDs and 11 current PhD students, over 200 
publications, and my recent election as president-elect of the 
International Society of Ocular Oncology, and now this chair, 
it is clear that the translational research in ocular oncology has 
come of age.
In The Netherlands, eye researchers collaborate. We started 
as ARVO-Chapter ARVO-Ned, and under the leadership of 
Imhof we have developed into a group called “Strijders against 
Blindness”. We now have the organization “Niet Blind” which 
is involved in raising money for eye research. Together, we are 
building a National Plan for Eye Research.
It is important that future ophthalmologists can perform 
research. As professor De Graeff told me before I started my 
PhD: “It is important to learn to understand the importance 
as well as the relativity of research.” We do not only need to 
train excellent researchers, but also train good clinicians who 
understand the literature, know the newest treatments and can 
apply them properly. By using our international connections, 
we can offer students in Medicine and Biosciences a chance 
to work in another country. Our lab is an example of 
“Internationalisation@home”, where Dutch and international 
students can learn about the attitude of international research. 
It is important to provide a heterogeneity in backgrounds. This 
spring, Athena’s Angels have drawn a lot of attention to the still 
present underrepresentation of women in the higher academic 
positions. Only by giving men and women and people from 
different cultural backgrounds the chance to participate in 
financial, organizational and leadership courses, will the 
academic staff and one day the professors have the diversity 
that has for a long time been present in students and PhD 
students. I am glad that our department under the leadership 
of Professor Luyten and Schalij has already developed such a 
heterogeneic character.
Back to the beginning of my presentation. I myself have felt 
a great affinity to Tiuri. After his return from his travels, he 
indicated that he would not have wished to have missed his 
experiences, although he had not become a knight like his 
colleagues. A friend said to him: “you do not have to wear a 
sword and shield to be a knight.” This is how I felt during recent 
years and how I tried to behave. It is unusual to become a 
professor in your own university after already having been made 
a member of the Academia Ophthalmologica Internationalis 
and the European Academy of Ophthalmology. I can put your 
mind to rest with regard to Tiuri: he was soon knighted as he 
had shown he had the right attributes to be a knight.
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Similar to him, I would not have liked to have missed my 
travels and my experiences.However, I hope, that with my new 
dignity, I will be able to do my work even better.
Word of thanks
I like to use this opportunity to thank several individuals. First, 
het College van Bestuur van de Leidse Universiteit and de Raad 
van Bestuur van het Leids Universitair Medisch Centrum, who 
made this appointment possible.
I also thank the Advisory Board for its persistance: during 
a period when the whole board of directors of the hospital 
changed, the committee under the guidance of Koning, stayed 
intact. I wish to thank Marjan Knijp for all her advice and 
support. You are terrific!
Professor Luyten, dear Gre: you now have a department with a 
lot of research and many grants. And about 25 PhD students? 
Thanks your creativity and capacity to build, our department 
has developed a lot. I am glad that you already early on saw the 
importance of my international connections.
Professor Schalij, dear Nicoline: your great capacity to organize 
things leads to good academic care, in which we are amongst 
the best, and always ahead of the pack. Thank you very much!
Many thanks to the workers and colleagues in the 
ophthalmology clinic and the lab, who support me in taking 
care of our patients and our research. You rock! PhD students, 
medical students, residents: it is a daily pleasure to work with 
you.
Many thanks to the many researchers in other departments 
of the hospital, especially the people at the Department of 
Immunohaematology and Clinical Oncology.
Professor van der Burg, dear Sjoerd, dear Thorbald van Hall, 
dear AG Jochemsen, dear Ewa 
Snaar, thank you for the collaboration. 
I furthermore thank the organizations that support our 
research, such as the Stichting Blinden-Penning, the 
LSBS, ANVVB, the SNOO, the Rotterdamse Stichting 
Blindenbelangen, het Nelly Reef Fonds, and the KWF. 
For new initiatives, we received the support of private people, 
and I especially wish to mention Mrs. Tine van Notten-van 
Royen, Mr Otto Röell, de heer en mevrouw Dirk and Nel 
Parlevliet, Ms. Alice Swalm and Mr. Piet Vrolijk. 
I thank my parents for giving me a good education: from both, 
I learned what is expected of a good doctor, and what science 
is, in which both excelled. My father was an ophthalmologist, 
my mother a genaecologist at the University of Amsterdam. I 
learned early on the importance of science, when on holiday 
in Drenthe, I did not have to come to dinner on time when 
I was counting migrating birds. My mother was my example 
that women can do anything, from my father I learned to look 
closely at things.
Dear friends, thank you all for coming. Many thanks to 
Marianne, Rinus, Erna, Marieke and Ton. Always warm, 
friendly, always there, even when we have not seen each other 
for a long time. That you are all here 40 years after we first 
met is terrific. Thanks to the many friends who know that I 
think of them, but who also know that my work (often) takes 
precedence.
Dear Lady Lions and partners, you are my extended family, and 
you are here en masse. You have been cut from the best cloth!
What I do comes forth from the example of some special 
teachers that I met during my study. My enthusiasm for tumor 
research comes from the fantastic lectures in biochemistry by 
professor van der Eb. I was later able to start my laboratory 
using your old equipment. For me they were like new. Dear 
Titia and Lex, thank you for all your support. Titia, I wear the 
gown of your father with much pride.
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Professors Sterk and De Keizer: you saw how important 
translational research was going to be and helped me to build a 
laboratory. Thank you very much.
Professor van Rood: you have influenced almost all steps 
of my career. My interest in immunology and HLA come 
forth from a lecture that you gave in the fourth year of my 
study. Great teachers can raise enthusiasm in their students. 
I wanted to do a PhD in your laboratory and managed to do 
that. When I had almost finished my PhD, you advised me, as 
Professor Querido had advised you, to visit the United States, 
a trip that influenced the rest of my life in many ways. When 
after spending several years in Miami, I wanted to return to 
Leiden, you and Lex van der Eb helped me through Macropa. 
When I wanted to apply for a KNAW grant, the Department of 
Ophthalmology did not have a professor, and you were ready 
to help out again. Great people help others.
You always know how to ask the right questions to help me 
find my way.
Dear Jon and Sacha, many thanks for your inspiration, the 
fantastic sailing, your support. I am very grateful to have run 
into such fantastic friends as you two.
Dear James Davis, dear Jim. Staying at your house in Miami 
is always a holiday. The love and support that you have given 
me for over 20 years are immeasurable. I learned from you the 
strength of kindness and of giving and I thank you with all my 
heart. Without you, I would not be who I am today.
Dear Wouter,
Attending a concert of Dead Mouse with you in a snow-
covered London was a special experience. Visiting the new 
proton center in Krakow showed me how much you have 
learned in Delft. It is great that you had just started at the 
Nikhef when the announcement of the gravity waves from 
outer space were being announced. I am glad I have such a fun 
nephew and I hope that with your study of physics you will be 
able to combine electronics and thinking.
My alter ego, my other half, dear Joke. We were together in my 
mother’s womb, we have been fighting, playing and working 
together since we were born. I learned very early on that 
together you achieve much more than alone. Sometimes we 
travel together, but often it is me who is on the road. We have 
contact every day, wherever I am. Your advice is very sensible, 
as fits an engineer. You look after me, often before I know I 
need help, as when I was leaving for Boston. You brought me a 
warm jacket and gloves. I had not noticed that even the Charles 
River was frozen over, but you had.
I have the best sister in the world and being a twin with you 
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Dr. Martine J. Jager is Professor of Ophthalmology, especially Ocular 
Melanoma, at Leiden University, The Netherlands. She received her 
MD degree and PhD in Immunology from Leiden University, did her 
residency in Ophthalmology at the University of Amsterdam, and a 
research and clinical ocular surface fellowship at the Bascom Palmer 
Eye Institute in Miami. She is a frequent visitor at the Schepens Eye 
Research institute, Harvard Medical School, Boston, where she holds 
a position as adjunct scientist. Her research interests are immunology 
and development of uveal melanoma, and ocular surface diseases, on 
which subjects she has published over 200 peer-reviewed papers as 
well as three books and over 40 book chapters. She is International 
Advisor and Guest Professor at Peking University, Bejing, China.
She mentors medical students and PhD student in the Netherlands 
as well as abroad. She has lectured worldwide, and has been principal 
investigator on numerous grants dealing with the development and 
immunology of uveal melanoma. Many projects involve international 
collaborations.
Dr. Jager has served as President of the Association for Research in 
Vision and Ophthalmology (ARVO), is a member of the Advisory 
Board of the International Council of Ophthalmology, and of the 
Academia Ophthalmologica Internationalis. She was recently elected to 
become the President of the International Society of Ocular Oncology.
Ocular melanoma is a rare type of cancer, with a high chance of metastases. 
Metastases of conjunctival and uveal melanoma are often resistant to 
therapy, including to immunological treatments. For uvea melanoma, this 
may be due to the environment in which this tumor arises, which is inside 
the eye. The eye has many immunological peculiarities: it is a location 
with immune privilege, which means that immune responses are down 
regulated. This has the advantage that corneal transplants will be accepted 
in a non-inflamed recipient cornea and thus usually not rejected. On the 
other hand, this immune privilege allows viruses such as ebola to proliferate 
inside the eye. Similarly, in mouse experiments, tumor cells may not be 
rejected when placed inside the eye, while they would be rejected when 
injected in the skin. Professor Jager’s research is focused on obtaining a 
better understanding of the influence of this immune privilege on the 
behavior of human ocular tumors, and on the possibilities of still using the 
immune system to develop an effective therapy to treat metastases of ocular 
melanoma.
In order to develop good research, (inter)national collaborations are 
essential. Within the LUMC, the department of Ophthalmology collaborates 
with the laboratories of Clinical Oncology, Immunohematology and 
Blood Transfusion, Human Genetics and Dermatology, among others. 
Collaborations also exist with the department of Ophthalmology and 
Clinical Genetics of the Erasmus MC, Rotterdam. Internationally, the 
research group of Professor Jager participates in the European Ocular 
Oncology group (which has led to the Horizon2020 Cure UM collaborative 
group), the International Society of Ocular Oncology, the American Joint 
Committee on Cancer and The Cancer Genome Atlas Project.
As a cornea specialist, Professor Jager treats patients with severe corneal 
and ocular surface diseases, searching for better treatments. A second 
international consortium, Horizon Arrest Blindness group, focusses on 
the immunological aspects of the cornea and stem cells, with the goal of 
developing an artificial cornea. 
 
